Abstract
The fixed dose combination of sitagliptin 50 mg and metformin 850 mg (Janumet ®), is indicated for the treatment of type 2 diabetes mellitus in addition to diet and exercise to improve glycemic control in patients treated with metformin alone. Methods: We report a 69-year-old man with type 2 diabetes that developed sudden loss of eyebrows and eyelashes about 4 months after the beginning of Janumet®.
Clinical and laboratory findings excluded the presence of systemic or skin diseases able to induce these manifestations, while the Naranjo probability scale documented a possible association between the drug and the adverse drug reaction.Keywords: Adverse drug reaction, metformin, sitagliptin, type 2 diabetes mellitus.
Current Drug Safety
Title:Loss of Eyebrows and Eyelashes During Concomitant Treatment with Sitagliptin and Metformin
Volume: 12 Issue: 1
Author(s): Elena Succurro, Caterina Palleria, Mariafrancesca Ruffo, Raffaele Serra, Franco Arturi and Luca Gallelli
Affiliation:
Keywords: Adverse drug reaction, metformin, sitagliptin, type 2 diabetes mellitus.
Abstract: The fixed dose combination of sitagliptin 50 mg and metformin 850 mg (Janumet ®), is indicated for the treatment of type 2 diabetes mellitus in addition to diet and exercise to improve glycemic control in patients treated with metformin alone. Methods: We report a 69-year-old man with type 2 diabetes that developed sudden loss of eyebrows and eyelashes about 4 months after the beginning of Janumet®.
Clinical and laboratory findings excluded the presence of systemic or skin diseases able to induce these manifestations, while the Naranjo probability scale documented a possible association between the drug and the adverse drug reaction.Export Options
About this article
Cite this article as:
Succurro Elena, Palleria Caterina, Ruffo Mariafrancesca, Serra Raffaele, Arturi Franco and Gallelli Luca, Loss of Eyebrows and Eyelashes During Concomitant Treatment with Sitagliptin and Metformin, Current Drug Safety 2017; 12 (1) . https://dx.doi.org/10.2174/1574886311666161014125536
DOI https://dx.doi.org/10.2174/1574886311666161014125536 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)
Recent Patents on Anti-Cancer Drug Discovery Heart Failure Models: Traditional and Novel Therapy
Current Vascular Pharmacology Effects of Drug Transporters on Pharmacological Responses and Safety
Current Drug Metabolism Collagen Receptors as Potential Targets for Novel Anti-Platelet Agents
Current Pharmaceutical Design Studies on Chloride Channels and their Modulators
Current Topics in Medicinal Chemistry Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Endothelial Progenitor Cells (EPCs) Evaluation in Aortic Aneurysm Repair
Current Vascular Pharmacology Regulation of Cholesterol Biosynthesis and Absorption: Ultimate Management of Dyslipidemia with Statin and Ezetimibe
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Therapeutic Potential of Resveratrol in Diabetic Nephropathy According to Molecular Signaling
Current Molecular Pharmacology Exploring the Potential of NO-Independent Stimulators and Activators of Soluble Guanylate Cyclase for the Medical Treatment of Erectile Dysfunction
Current Pharmaceutical Design The Predictive Value of Lipid Markers in Vascular Disease
Current Pharmaceutical Design Chronic Inflammatory Diseases: Progress and Prospect with Herbal Medicine
Current Pharmaceutical Design Recent Advances in Exercise Testing
Current Cardiology Reviews Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced Prostate Cancer
Current Drug Targets Lipid-lowering Drug Therapy in Elderly Patients
Current Pharmaceutical Design Palliative Combined Percutaneous Balloon Aortic Valvuloplasty and Unprotected Left Main Stenting in End Stage Renal Disease
Current Cardiology Reviews Potential Role of Inflammation in Associations between Particulate Matter and Heart Failure
Current Pharmaceutical Design Thymosin β4 Protein Therapy for Cardiac Repair
Current Pharmaceutical Design Novel Nanostructured Polymeric Carriers to Enable Drug Delivery for Cardiovascular Diseases
Current Pharmaceutical Design Clinical Experience with the Use of Angiotensin Receptor Blockers in Patients with Cardiovascular, Cerebrovascular and Renal Diseases
Current Clinical Pharmacology 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry